Consensus on the development of vaccines against naturally acquired melioidosis

Direk Limmathurotsakul, Simon G P Funnell, Alfredo Torres, Lisa A. Morici, Paul J. Brett, Susanna Dunachie, Timothy Atkins, Daniel M. Altmann, Gregory Bancroft, Sharon J. Peacock

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Several candidates for a vaccine against Burkholderia pseudomallei, the causal bacterium of melioidosis, have been developed, and a rational approach is now needed to select and advance candidates for testing in relevant nonhuman primate models and in human clinical trials. Development of such a vaccine was the topic of a meeting in the United Kingdom in March 2014 attended by international candidate vaccine developers, researchers, and government health officials. The focus of the meeting was advancement of vaccines for prevention of natural infection, rather than for protection from the organism’s known potential for use as a biological weapon. A direct comparison of candidate vaccines in well-characterized mouse models was proposed. Knowledge gaps requiring further research were identified. Recommendations were made to accelerate the development of an effective vaccine against melioidosis.

Original languageEnglish (US)
Pages (from-to)e1-e7
JournalEmerging Infectious Diseases
Volume21
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Melioidosis
Consensus
Vaccines
Biological Warfare Agents
Burkholderia pseudomallei
Primates
Research Personnel
Clinical Trials
Bacteria
Health
Infection
Research

ASJC Scopus subject areas

  • Epidemiology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Limmathurotsakul, D., Funnell, S. G. P., Torres, A., Morici, L. A., Brett, P. J., Dunachie, S., ... Peacock, S. J. (2015). Consensus on the development of vaccines against naturally acquired melioidosis. Emerging Infectious Diseases, 21(6), e1-e7. https://doi.org/10.3201/eid2106.141480

Consensus on the development of vaccines against naturally acquired melioidosis. / Limmathurotsakul, Direk; Funnell, Simon G P; Torres, Alfredo; Morici, Lisa A.; Brett, Paul J.; Dunachie, Susanna; Atkins, Timothy; Altmann, Daniel M.; Bancroft, Gregory; Peacock, Sharon J.

In: Emerging Infectious Diseases, Vol. 21, No. 6, 01.06.2015, p. e1-e7.

Research output: Contribution to journalArticle

Limmathurotsakul, D, Funnell, SGP, Torres, A, Morici, LA, Brett, PJ, Dunachie, S, Atkins, T, Altmann, DM, Bancroft, G & Peacock, SJ 2015, 'Consensus on the development of vaccines against naturally acquired melioidosis', Emerging Infectious Diseases, vol. 21, no. 6, pp. e1-e7. https://doi.org/10.3201/eid2106.141480
Limmathurotsakul, Direk ; Funnell, Simon G P ; Torres, Alfredo ; Morici, Lisa A. ; Brett, Paul J. ; Dunachie, Susanna ; Atkins, Timothy ; Altmann, Daniel M. ; Bancroft, Gregory ; Peacock, Sharon J. / Consensus on the development of vaccines against naturally acquired melioidosis. In: Emerging Infectious Diseases. 2015 ; Vol. 21, No. 6. pp. e1-e7.
@article{628686f086904ad4bc8960c8ae238428,
title = "Consensus on the development of vaccines against naturally acquired melioidosis",
abstract = "Several candidates for a vaccine against Burkholderia pseudomallei, the causal bacterium of melioidosis, have been developed, and a rational approach is now needed to select and advance candidates for testing in relevant nonhuman primate models and in human clinical trials. Development of such a vaccine was the topic of a meeting in the United Kingdom in March 2014 attended by international candidate vaccine developers, researchers, and government health officials. The focus of the meeting was advancement of vaccines for prevention of natural infection, rather than for protection from the organism’s known potential for use as a biological weapon. A direct comparison of candidate vaccines in well-characterized mouse models was proposed. Knowledge gaps requiring further research were identified. Recommendations were made to accelerate the development of an effective vaccine against melioidosis.",
author = "Direk Limmathurotsakul and Funnell, {Simon G P} and Alfredo Torres and Morici, {Lisa A.} and Brett, {Paul J.} and Susanna Dunachie and Timothy Atkins and Altmann, {Daniel M.} and Gregory Bancroft and Peacock, {Sharon J.}",
year = "2015",
month = "6",
day = "1",
doi = "10.3201/eid2106.141480",
language = "English (US)",
volume = "21",
pages = "e1--e7",
journal = "Emerging Infectious Diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention (CDC)",
number = "6",

}

TY - JOUR

T1 - Consensus on the development of vaccines against naturally acquired melioidosis

AU - Limmathurotsakul, Direk

AU - Funnell, Simon G P

AU - Torres, Alfredo

AU - Morici, Lisa A.

AU - Brett, Paul J.

AU - Dunachie, Susanna

AU - Atkins, Timothy

AU - Altmann, Daniel M.

AU - Bancroft, Gregory

AU - Peacock, Sharon J.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Several candidates for a vaccine against Burkholderia pseudomallei, the causal bacterium of melioidosis, have been developed, and a rational approach is now needed to select and advance candidates for testing in relevant nonhuman primate models and in human clinical trials. Development of such a vaccine was the topic of a meeting in the United Kingdom in March 2014 attended by international candidate vaccine developers, researchers, and government health officials. The focus of the meeting was advancement of vaccines for prevention of natural infection, rather than for protection from the organism’s known potential for use as a biological weapon. A direct comparison of candidate vaccines in well-characterized mouse models was proposed. Knowledge gaps requiring further research were identified. Recommendations were made to accelerate the development of an effective vaccine against melioidosis.

AB - Several candidates for a vaccine against Burkholderia pseudomallei, the causal bacterium of melioidosis, have been developed, and a rational approach is now needed to select and advance candidates for testing in relevant nonhuman primate models and in human clinical trials. Development of such a vaccine was the topic of a meeting in the United Kingdom in March 2014 attended by international candidate vaccine developers, researchers, and government health officials. The focus of the meeting was advancement of vaccines for prevention of natural infection, rather than for protection from the organism’s known potential for use as a biological weapon. A direct comparison of candidate vaccines in well-characterized mouse models was proposed. Knowledge gaps requiring further research were identified. Recommendations were made to accelerate the development of an effective vaccine against melioidosis.

UR - http://www.scopus.com/inward/record.url?scp=84981749578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981749578&partnerID=8YFLogxK

U2 - 10.3201/eid2106.141480

DO - 10.3201/eid2106.141480

M3 - Article

C2 - 25992835

AN - SCOPUS:84981749578

VL - 21

SP - e1-e7

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

SN - 1080-6040

IS - 6

ER -